PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 31195189-7 2019 However, treatment with 200 mg of metformin was more effective in increasing neurotrophic (myelin basic protein and neural growth factor), angiogenic (vascular endothelial growth factor) and anti-inflammatory (inhibitor kappa B-alpha and interleukin 10) factors. Metformin 34-43 interleukin 10 Mus musculus 238-252 34570348-7 2021 Moreover, metformin treatment significantly downregulated the expression of pro-inflammatory associated genes (iNOS, H2-Aa, and TNF-alpha) in the corpus callosum, whereas expression of anti-inflammatory markers (Arg1, Mrc1, and IL10) was not promoted, compared to CPZ mice. Metformin 10-19 interleukin 10 Mus musculus 228-232 31904843-8 2020 RESULTS: Metformin enhanced the immunomodulatory functions of Ad-MSCs including IDO, IL-10 and TGF-beta. Metformin 9-18 interleukin 10 Mus musculus 85-90 31904843-10 2020 STAT1 inhibition by siRNA strongly diminished IDO, IL-10, TGF-beta in metformin-treated Ad-MSCs. Metformin 70-79 interleukin 10 Mus musculus 51-56 29899823-6 2018 Metformin treatment increased the number of lung CD8-effector-memory T and CD4+Foxp3+IL-10+ T cells in B16F10-transplanted mice. Metformin 0-9 interleukin 10 Mus musculus 85-90 31268904-9 2019 RESULTS: Metformin improved Ox-LDL-impaired anti-inflammatory phenotype in raw264.7 macrophages as shown by up-regulated transcription of anti-inflammatory markers including interleukin 10 (0.76 +- 0.04 vs. 0.94 +- 0.01, P = 0.003) and Resistin-like molecule alpha (0.67 +- 0.08 vs. 1.78 +- 0.34, P = 0.030). Metformin 9-18 interleukin 10 Mus musculus 174-188 30218721-9 2019 Moreover, metformin increased Ox-LDL-impaired IL-10 secretion, an important anti-foam cell cytokine in atherosclerosis. Metformin 10-19 interleukin 10 Mus musculus 46-51 31164166-12 2019 In addition, metformin reduced B cell differentiation into germinal center B cells, decreased the serum immunoglobulin G level, and maintained the balance between IL-10- and IL-17-producing B cells. Metformin 13-22 interleukin 10 Mus musculus 163-179 30134793-7 2018 Treatment with metformin inhibited these variations and promoted the release of cytokine IL-10 with anti-inflammatory capability. Metformin 15-24 interleukin 10 Mus musculus 89-94 30134793-8 2018 In vivo, metformin reduced the production of pro-inflammatory cytokines, osteoclastogenesis, and osteolysis, increasing IL-10 production. Metformin 9-18 interleukin 10 Mus musculus 120-125 24716225-13 2014 Metformin significantly attenuated the severity of colitis in IL-10-/- mice, induced AMPK activity in intestinal epithelial cells, and inhibited the development of colitic cancer in mice. Metformin 0-9 interleukin 10 Mus musculus 62-67 28002460-0 2016 Metformin Improves Ileal Epithelial Barrier Function in Interleukin-10 Deficient Mice. Metformin 0-9 interleukin 10 Mus musculus 56-70 28002460-11 2016 In correlation, the mRNA level of differentiation regulator including bmp4, bmpr2 and math1 were also increased in IL10KO mice supplemented with metformin, which likely explains the enhanced epithelial differentiation in IL10KO mice with metformin. Metformin 145-154 interleukin 10 Mus musculus 115-119 28002460-11 2016 In correlation, the mRNA level of differentiation regulator including bmp4, bmpr2 and math1 were also increased in IL10KO mice supplemented with metformin, which likely explains the enhanced epithelial differentiation in IL10KO mice with metformin. Metformin 238-247 interleukin 10 Mus musculus 115-119 24009539-6 2013 On the other hand, the protein expressions of anti-inflammatory cytokines, IL-4 and IL-10, were enhanced or maintained by metformin. Metformin 122-131 interleukin 10 Mus musculus 84-89